Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

The WHO issued a global recommendation for lenacapavir, a highly effective, twice-yearly injection to prevent HIV infection. The recommendation follows a recent FDA approval for the drug, which ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. The regulatory body approved lenacapavir, under the ...

Trump's aid cuts impact HIV prevention in Africa, leaving vulnerable groups at risk Trump says U.S. pays too much in foreign aid, wants others to help shoulder burden PEPFAR provision of ...

If we shift HIV prevention back to clinical systems, we risk destroying those safe spaces. Long-acting injectables might require clients to go back to those places which they actively avoided.

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

FDA approves twice-a-year HIV prevention drug that could help end the virus worldwide It reduces transmissions by up to 96%, but now world governments and big-dollar funders will need to step in.

The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

While a vaccine to prevent HIV still is needed, some experts say this new shot could be the next best thing.

It's the world's first twice-yearly shot and was shown in trials to be 96% effective at preventing HIV. Advocates call it a gamechanger.

Young health professionals from Phoenix, Verulam, and Tongaat in Durban have been recognised by the South African Medical Research Council (SAMRC) as trailblazers in health and science.

While a vaccine to prevent HIV still is needed, some experts say the new shot could be the next best thing.